Development of affordable effective vaccines against whooping cough for the developing world

Journal of Vaccines and Vaccination

Volumn 3, Issue 3, 2012, Pages

  Mukkur, Trilochan ^a   Richmond, Peter ^b  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879826517     PISSN: None     EISSN: 21577560     Source Type: Journal    
DOI: 10.4172/2157-7560.1000e107     Document Type: Editorial

References (14)

1. (2011) National Network for Immunization Information.
2. (1996) Update: Vaccine Side Effects, Adverse Reactions, Contraindications, and Precautions Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 45: 1-35.
3. Poolman JT, Hallander H, Halperin SA [2011] Pertussis vaccines: where to now? Expert Rev Vaccines 10: 1497-1500.
4. Julie Milstien, Sarah Glass, Amie Batson, Michel Greco, Jacques Berger (2002) Divergence of vaccine product lines in industrialized and developing countries.
5. Kamachi K, Konda T, Arakawa Y (2003) DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice. Vaccine 21: 4609-4615.
6. Li QT, Zhu YZ, Chu JY, Dong K, He P, et al. (2006) Granulocyte-macrophage colony-stimulating factor DNA prime-protein boost strategy to enhance efficacy of a recombinant pertussis DNA vaccine. Acta Pharmacol Sin 27: 1487-1494.
7. Fry SR, Chen AY, Daggard G, Mukkur TK (2008) Parenteral immunization of mice with a genetically inactivated pertussis toxin DNA vaccine induces cellmediated immunity and protection. J Med Microbiol 57: 28-35.
8. Conway MA, Madrigal-Estebas L, McClean S, Brayden DJ, Mills KH (2001) Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine 19: 1940-1950.
9. Hoiseth SK, Stocker BA (1981) Aromatic-dependent Salmonella typhimurium are non-virulent and are effective live vaccines. Nature 291: 238-239.
10. Curtiss R 3rd, Kelly SM (1987) Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect Immun 55: 3035-3043.
11. Cornford-Nairns R, Daggard G, Mukkur T (2012) Construction and Preliminary Immunobiological Characterization of a Novel, Non-Reverting, Intranasal Live Attenuated Whooping Cough Vaccine Candidate. J Microbiol Biotechnol 22: 856-865.
12. Mielcarek N, Debrie AS, Raze D, Bertout J, Rouanet C, et al. (2006) Live attenuated B. pertussis as a single-dose nasal vaccine against whoopingcough. PLoS Pathog 2: e65.
13. Milstein J, Belgharbi L (2004) Regulatory pathways for vaccines for developing countries. Bull World Health Organ 82: 128-133.
14. Coudeville L, Van Rie A, Getsios D, Caro JJ, Crépey P, et al. (2009) Adult Vaccination Strategies for the Control of Pertussis in the United States: An economic evaluation including the dynamic population effects. PLoS ONE 4: e6284.